Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) - Trial NCT03501550
Access comprehensive clinical trial information for NCT03501550 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cocrystal Pharma, Inc. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cocrystal Pharma, Inc.
Timeline & Enrollment
Phase 2
Jun 26, 2018
Jun 07, 2019
Primary Outcome
Number of Subjects With Treatment Emergent Adverse Events,Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After Treatment
Summary
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir
 followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic
 hepatitis C (HCV) genotype 1 (GT1) infection
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03501550
Non-Device Trial